Wilms’ tumor gene 1 in hematological malignancies: friend or foe?

References

• Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60(3):509–520. doi:10.1016/0092-8674(90)90601-A
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Suarez Saiz F, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868–876. doi:10.1038/sj.leu.2404624
   PubMed Web of Science ®Google Scholar
• Qi XW, Zhang F, Wu H, et al. Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep. 2015;5:8924. doi:10.1038/srep08924
   PubMed Web of Science ®Google Scholar
• Rampal R, Figueroa ME. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica. 2016;101(6):672–679. doi:10.3324/haematol.2015.141796
   PubMed Web of Science ®Google Scholar
• Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222–5231. doi:10.1182/blood-2009-12-259390
   PubMed Web of Science ®Google Scholar
• Luo P, Jing W, Yi K, et al. Wilms’ tumor 1 gene in hematopoietic malignancies: clinical implications and future directions. Leuk Lymphoma. 2020;61(9):2059–2067. doi:10.1080/10428194.2020.1762884
   PubMed Web of Science ®Google Scholar
• Awada H, Durmaz A, Gurnari C, et al. The genomic landscape of Wilms’ tumor 1 (WT1) mutant acute myeloid leukemia. Blood. 2020;136(Supplement 1):28.
   Google Scholar
• Ahmad EI, El-Akad GM, Ismail WI, et al. Study of Wilms’ tumor 1 gene expression in patients with acute myeloid leukemia. Egypt J Haematol. 2019;44(4):195–203. doi:10.4103/ejh.ejh_26_19
   Web of Science ®Google Scholar
• Adnan-Awad S, Meligui YME, Salem SE, et al. Prognostic impact of WT-1 and survivin gene expression in acute myeloid leukemia patients. Clin Lab. 2019;65(4):435–444.
   Web of Science ®Google Scholar
• Augsberger C, Hänel G, Xu W, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody. Blood. 2021;138(25):2655–2669. doi:10.1182/blood.2020010477
   PubMed Web of Science ®Google Scholar
• Shandilya J, Roberts SG. A role of WT1 in cell division and genomic stability. Cell Cycle. 2015;14(9):1358–1364. doi:10.1080/15384101.2015.1021525
   PubMed Web of Science ®Google Scholar
• Chau YY, Hastie ND. The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet. 2012;28(10):515–524. doi:10.1016/j.tig.2012.04.004
   PubMed Web of Science ®Google Scholar
• Wilm B, Muñoz-Chapuli R. The role of WT1 in embryonic development and normal organ homeostasis. Meth Mol Biol. 2016; 1467:23–39. doi:10.1007/978-1-4939-4023-3_3
   PubMedGoogle Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–5201. doi:10.1200/JCO.2009.22.4865
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms’ tumour gene is involved in genitourinary development. Nature. 1990;346(6280):194–197. doi:10.1038/346194a0
   PubMed Web of Science ®Google Scholar
• Ullmark T, Montano G, Gullberg U. DNA and RNA binding by the Wilms’ tumour gene 1 (WT1) protein + KTS and -KTS isoforms-from initial observations to recent global genomic analyses. Eur J Haematol. 2018;100(3):229–240. doi:10.1111/ejh.13010
   PubMed Web of Science ®Google Scholar
• Haber DA, Sohn RL, Buckler AJ, et al. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA. 1991;88(21):9618–9622. doi:10.1073/pnas.88.21.9618
   PubMed Web of Science ®Google Scholar
• Kramarzova K, Stuchly J, Willasch A, et al. Real-time PCR quantification of major Wilms’ tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia. 2012;26(9):2086–2095. doi:10.1038/leu.2012.76
   PubMed Web of Science ®Google Scholar
• Klamt B, Koziell A, Poulat F, et al. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/−KTS splice isoforms. Hum Mol Genet. 1998;7(4):709–714. doi:10.1093/hmg/7.4.709
   PubMed Web of Science ®Google Scholar
• Potluri S, Assi SA, Chin PS, et al. Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1. Cell Rep. 2021;35(3):109010. doi:10.1016/j.celrep.2021.109010
   PubMed Web of Science ®Google Scholar
• Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell. 1993;74(4):679–691. doi:10.1016/0092-8674(93)90515-R
   PubMed Web of Science ®Google Scholar
• Duim SN, Goumans MJ, Kruithof BPT. WT1 in cardiac development and disease. In: van den Heuvel-Eibrink MM, editor. Wilms tumor. Brisbane, AU: Codon; 2016.
   Google Scholar
• Herzer U, Crocoll A, Barton D, et al. The Wilms tumor suppressor gene wt1 is required for development of the spleen. Curr Biol. 1999;9(15):837–840. doi:10.1016/S0960-9822(99)80369-8
   PubMed Web of Science ®Google Scholar
• Ijpenberg A, Pérez-Pomares JM, Guadix JA, et al. Wt1 and retinoic acid signaling are essential for stellate cell development and liver morphogenesis. Dev Biol. 2007;312(1):157–170. doi:10.1016/j.ydbio.2007.09.014
   PubMed Web of Science ®Google Scholar
• Cano E, Carmona R, Muñoz-Chápuli R. Wt1-expressing progenitors contribute to multiple tissues in the developing lung. Am J Phys Lung Cell Mol Physiol. 2013;305(4):L322–L332. doi:10.1152/ajplung.00424.2012
   PubMed Web of Science ®Google Scholar
• Ariza L, Cañete A, Rojas A, et al. Role of the Wilms’ tumor suppressor gene Wt1 in pancreatic development. Dev Dyn. 2018;247(7):924–933. doi:10.1002/dvdy.24636
   PubMed Web of Science ®Google Scholar
• Wagner KD, Wagner N, Vidal VP, et al. The Wilms’ tumor gene Wt1 is required for normal development of the retina. EMBO J. 2002;21(6):1398–1405. doi:10.1093/emboj/21.6.1398
   PubMed Web of Science ®Google Scholar
• Ito K, Oji Y, Tatsumi N, et al. Antiapoptotic function of 17AA(+)WT1 (Wilms’ tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene. 2006;25(30):4217–4229. doi:10.1038/sj.onc.1209455
   PubMed Web of Science ®Google Scholar
• Gu WY, Chen ZX, Hu SY, et al. Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. Haematologica. 2005;90(3):403–405.
   PubMed Web of Science ®Google Scholar
• Bissanum R, Lirdprapamongkol K, Svasti J, et al. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells. Biochem Biophys Res Commun. 2017;494(1-2):256–262. doi:10.1016/j.bbrc.2017.10.043
   PubMed Web of Science ®Google Scholar
• Oji Y, Tatsumi N, Kobayashi J, et al. Wilms’ tumor gene WT1 promotes homologous recombination-mediated DNA damage repair. Mol Carcinog. 2015;54(12):1758–1771. doi:10.1002/mc.22248
   PubMed Web of Science ®Google Scholar
• Yao YY, Chai XX, Gong C, et al. WT1 inhibits AML cell proliferation in a p53-dependent manner. Cell Cycle. 2021;20(16):1552–1560. doi:10.1080/15384101.2021.1951938
   PubMed Web of Science ®Google Scholar
• Cao LX, Zhang J, Ren HJ, et al. Effect of down-regulation of miR-23b-3p on the differentiation of acute myeloid leukemia via Wilms cancer gene 1. J Biomater Tissue Eng. 2021;11(7):1377–1382. doi:10.1166/jbt.2021.2696
   Web of Science ®Google Scholar
• Zhou B, Jin XH, Jin WW, et al. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target. J Transl Med. 2020;18(1).
   Web of Science ®Google Scholar
• Lyu Y, Lou J, Yang Y, et al. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia. 2017;31(12):2543–2551. doi:10.1038/leu.2017.116
   PubMed Web of Science ®Google Scholar
• Liu JM, Li M, Luo W, et al. Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis. Lab Invest. 2021;101(10):1308–1317. doi:10.1038/s41374-021-00640-3
   PubMed Web of Science ®Google Scholar
• Christopher MJ, Katerndahl CDS, LeBlanc HR, et al. Tumor suppressor function of WT1 in acute promyelocytic leukemia. Haematologica. 2021;107(1):342–346. doi:10.3324/haematol.2021.279601
   Web of Science ®Google Scholar
• Christopher M, Menssen A, Gang M, et al. Expression of the tumor suppressor WT1 Is induced By PML-rara in acute promyelocytic leukemia. Â. Blood. 2017;130:2508.
   Web of Science ®Google Scholar
• Wagstaff M, Tsaponina O, Caalim G, et al. Crosstalk between β-catenin and WT1 signaling activity in acute myeloid leukemia. Haematologica. 2023;108(1):283–289. doi:10.3324/haematol.2021.280294
   PubMed Web of Science ®Google Scholar
• Wang Y, Weng WJ, Zhou DH, et al. Wilms tumor 1 mutations are independent poor prognostic factors in pediatric acute myeloid leukemia. Front Oncol. 2021;11:632094. doi:10.3389/fonc.2021.632094
   PubMed Web of Science ®Google Scholar
• Marceau-Renaut A, Duployez N, Ducourneau B, et al. Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the French ELAM02 study group. Hemasphere. 2018;2(1):e31. doi:10.1097/HS9.0000000000000031
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang YX, Huang T, et al. Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. Int J Lab Hematol. 2018;40(4):408–418. doi:10.1111/ijlh.12802
   PubMed Web of Science ®Google Scholar
• Liu H, Wang X, Zhang H, et al. Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation. Mol Med Rep. 2019;20(3):2426–2432.
   PubMed Web of Science ®Google Scholar
• Duléry R, Nibourel O, Gauthier J, et al. Impact of Wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52(4):539–543. doi:10.1038/bmt.2016.318
   PubMed Web of Science ®Google Scholar
• Deng DX, Wen JJ, Cheng YF, et al. Wilms’ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. BMC Cancer. 2021;21(1):292. doi:10.1186/s12885-021-08022-0
   PubMed Web of Science ®Google Scholar
• Qin YZ, Wang Y, Xu LP, et al. Subgroup analysis can optimize the relapse-prediction cutoff value for WT1 expression after allogeneic hematologic stem cell transplantation in acute myeloid leukemia. J Mol Diagn. 2020;22(2):188–195. doi:10.1016/j.jmoldx.2019.10.003
   PubMed Web of Science ®Google Scholar
• Cho BS, Min GJ, Kim H, et al. Measurable residual disease assay with WT1 expression in acute myeloid leukemia Who underwent allogeneic hematopoietic stem cell transplantation; optimal threshold, time points, and candidates. Blood. 2018;132(Supplement 1):2759. doi:10.1182/blood-2018-99-110042
   Google Scholar
• Yoon JH, Kim HJ, Park SS, et al. Clinical outcome of autologous hematopoietic cell transplantation in adult patients with acute myeloid leukemia: who may benefit from autologous hematopoietic cell transplantation? Biol Blood Marrow Transpt. 2017;23(4):588–597. doi:10.1016/j.bbmt.2017.01.070
   PubMed Web of Science ®Google Scholar
• Valkova V, Vydra J, Markova M, et al. WT1 gene expression in peripheral blood before and after allogeneic stem cell transplantation is a clinically relevant prognostic marker in AML – a single-center 14-year experience. Clin Lymphoma Myeloma Leuk. 2021;21(2):e145–e151. doi:10.1016/j.clml.2020.09.008
   PubMed Web of Science ®Google Scholar
• Ido K, Nakamae M, Koh H, et al. The proportional relationship between pretransplant WT1 mRNA levels and risk of mortality after allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in remission. Transplantation. 2019;103(10):2201–2210. doi:10.1097/TP.0000000000002662
   PubMed Web of Science ®Google Scholar
• Candoni A, De Marchi F, Zannier ME, et al. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission. Leuk Res. 2017;63:22–27. doi:10.1016/j.leukres.2017.10.010
   PubMed Web of Science ®Google Scholar
• Candoni A, De Marchi F, Zanini F, et al. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Exp Hematol. 2017;49:25–33. doi:10.1016/j.exphem.2017.01.005
   PubMed Web of Science ®Google Scholar
• Rautenberg C, Lauseker M, Kaivers J, et al. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. Eur J Haematol. 2021;107(2):283–292. doi:10.1111/ejh.13664
   PubMed Web of Science ®Google Scholar
• Mashima K, Oh I, Ikeda T, et al. Role of sequential monitoring of WT1 gene expression in patients with acute myeloid leukemia for the early detection of leukemia relapse. Clin Lymphoma Myeloma Leuk. 2018;18(12):e521–e527. doi:10.1016/j.clml.2018.07.298
   PubMed Web of Science ®Google Scholar
• Ikeno S, Seto A, Sato T, et al. Retrospective analyses of wilms tumor gene-1 expression in acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Tr. 2018;24(3):S234. doi:10.1016/j.bbmt.2017.12.218
   Web of Science ®Google Scholar
• Rautenberg C, Pechtel S, Hildebrandt B, et al. Wilms’ tumor 1 gene expression using a standardized European LeukemiaNet-certified assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(11):2337–2343. doi:10.1016/j.bbmt.2018.05.011
   PubMed Web of Science ®Google Scholar
• De Marchi F, Candoni A, Zannier ME, et al. Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker? Am J Hematol. 2017;92(5):E72–E74. doi:10.1002/ajh.24686
   PubMed Web of Science ®Google Scholar
• Larisa G, Irina B, Rinat B, et al. Early reduction of WT1 transcript level during induction chemotherapy predicts for longer relapse-free and overall survival in de novo intermediate risk acute myeloid leukemia. Cl Lymph Myelom Leuk. 2018;18:S198.
   Web of Science ®Google Scholar
• Hao Y, Cheng Y, Wu Q, et al. Combined usage of Wilms’ tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation. Exp Ther Med. 2018;15(2):1403–1409.
   PubMed Web of Science ®Google Scholar
• Guolo F, Minetto P, Clavio M, et al. Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. Haematologica. 2017;102(9):e348–e351. doi:10.3324/haematol.2017.167254
   PubMed Web of Science ®Google Scholar
• Giudice V, Gorrese M, Vitolo R, et al. WT1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes. Biomedicines. 2021;9(4):387. doi:10.3390/biomedicines9040387
   PubMed Web of Science ®Google Scholar
• Šálek C, Vydra J, Cerovská E, et al. WT1 expression in peripheral blood at diagnosis and during the course of early consolidation treatment correlates with survival in patients With intermediate and poor-risk acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(12):e998–e1009. doi:10.1016/j.clml.2020.07.014
   PubMed Web of Science ®Google Scholar
• Du D, Zhu L, Wang Y, et al. Expression of WT1 gene and its prognostic value in patients with acute myeloid leukemia. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(1):50–57.
   PubMedGoogle Scholar
• Martinez-Laperche C, Kwon M, Franco-Villegas AC, et al. Wilms tumor 1 gene expression levels improve risk stratification in AML patients. results of a multicentre study within the spanish group for molecular biology in haematology. Br J Haematol. 2018;181(4):542–546. doi:10.1111/bjh.14635
   PubMed Web of Science ®Google Scholar
• Marjanovic I, Karan-Djurasevic T, Ugrin M, et al. Use of Wilms tumor 1 gene expression as a reliable marker for prognosis and minimal residual disease monitoring in acute myeloid leukemia With normal karyotype patients. Clin Lymphoma Myeloma Leuk. 2017;17(5):312–319. doi:10.1016/j.clml.2016.12.006
   PubMed Web of Science ®Google Scholar
• Frairia C, Aydin S, Audisio E, et al. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: a retrospective cohort study. Leuk Res. 2017;61:10–17. doi:10.1016/j.leukres.2017.08.008
   PubMed Web of Science ®Google Scholar
• Lambert J, Lambert J, Thomas X, et al. Early detection of WT1 measurable residual disease identifies high-risk patients independently of transplantation in AML. Blood Adv. 2021;5(23):5258. doi:10.1182/bloodadvances.2021004322
   PubMed Web of Science ®Google Scholar
• Yoon JH, Kim HJ, Kwak DH, et al. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study. J Hematol Oncol. 2017;10(1):30. doi:10.1186/s13045-017-0404-4
   PubMedGoogle Scholar
• Cho BS, Shin SH, Lee SE, et al. Clinical outcomes of decitabine and the role of WT-1 expression as a surrogate prognostic marker for patients with elderly acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:S200–S201.
   Web of Science ®Google Scholar
• Bani-Ahmad MA, Al-Sweedan SA, Al-Asseiri MA, et al. A proposed kinetic model for the diagnostic and prognostic value of WT1 and p53 in acute myeloid leukemia. Clin Lab. 2018;64(3):357–363.
   PubMed Web of Science ®Google Scholar
• Hidaka D, Onozawa M, Hashiguchi J, et al. Wilms tumor 1 expression at diagnosis correlates With genetic abnormalities and polymorphism but is not independently prognostic in acute myelogenous leukemia: a hokkaido leukemia net study. Clin Lymphoma Myeloma Leuk. 2018;18(11):e469–e479. doi:10.1016/j.clml.2018.07.291
   PubMed Web of Science ®Google Scholar
• Mitrovic M, Kostic T, Virijevic M, et al. The influence of Wilms’ tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients. Int J Lab Hematol. 2020;42(1):82–87. doi:10.1111/ijlh.13144
   PubMed Web of Science ®Google Scholar
• Niktoreh N, Walter C, Zimmermann M, et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019;2019:1609128.
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Kohlschmidt J, Orwick S, et al. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: alliance for clinical trials in oncology study. Blood Adv. 2023;7(16):4671–4675. doi:10.1182/bloodadvances.2023010482
   PubMed Web of Science ®Google Scholar
• El Hussein S, DiNardo CD, Takahashi K, et al. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022;57(3):370–376. doi:10.1038/s41409-021-01538-w
   PubMed Web of Science ®Google Scholar
• Tien FM, Hou HA, Tang JL, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018;103(11):e510–e513. doi:10.3324/haematol.2018.189043
   PubMed Web of Science ®Google Scholar
• Petiti J, Rosso V, Lo Iacono M, et al. Prognostic significance of The Wilms’ Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia. Leuk Res. 2018;67:6–11. doi:10.1016/j.leukres.2018.01.016
   PubMed Web of Science ®Google Scholar
• Bedair HM, Attia MH, Gohar SF, et al. The prognostic impact of wilms tumor-1 polymorphism (rs16754) and human myeloid inhibitory C-type lectin-like receptor expression in cytogenetically normal-acute myeloid leukemia. Egyptian J. Med Human Genet. 2021;22(1).
   PubMedGoogle Scholar
• Ramzi M, Moghadam M, Cohan N. Wilms tumor-1 (WT1) rs16754 polymorphism and clinical outcome in acute myeloid leukemia. Turk J Haematol. 2019;36(1):67–68. doi:10.4274/tjh.galenos.2018.2018.0277
   PubMed Web of Science ®Google Scholar
• Toogeh G, Ramzi M, Faranoush M, et al. Prevalence and prognostic impact of Wilms’ tumor 1 (WT1) gene, including SNP rs16754 in cytogenetically normal acute myeloblastic leukemia (CN-AML): an Iranian experience. Clin Lymphoma Myeloma Leuk. 2016;16(3):e21–e26. doi:10.1016/j.clml.2015.11.017
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE, Herrero MJ, Rojas L, et al. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia. Pharmacogenomics J. 2016;16(1):30–40. doi:10.1038/tpj.2015.80
   PubMed Web of Science ®Google Scholar
• Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood. 2009;114(5):1038–1045. doi:10.1182/blood-2008-12-192039
   PubMed Web of Science ®Google Scholar
• Bordin F, Piovan E, Masiero E, et al. WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica. 2018;103(2):266–277. doi:10.3324/haematol.2017.170431
   PubMed Web of Science ®Google Scholar
• Roy U, Raghavan SC. Deleterious point mutations in T-cell acute lymphoblastic leukemia: mechanistic insights into leukemogenesis. Int J Cancer. 2021;149(6):1210–1220. doi:10.1002/ijc.33527
   PubMed Web of Science ®Google Scholar
• Rodrigues GOL, Cramer SD, Winer HY, et al. Mutations that collaborate with IL-7Ra signaling pathways to drive ALL. Adv Biol Regul. 2021;80:100788. doi:10.1016/j.jbior.2021.100788
   PubMedGoogle Scholar
• Wang SJ, Wang C, Li T, et al. WT1 overexpression predicted good outcomes in adult B-cell acute lymphoblastic leukemia patients receiving chemotherapy. Hematology. 2020;25(1):118–124. doi:10.1080/16078454.2020.1735670
   PubMed Web of Science ®Google Scholar
• Mikhael NL, Ibrahim AM, Helmy MA, et al. Wilms’ tumor gene (WT1) expression levels as prognostic marker in pediatric acute lymphoblastic leukemia. Egypt J Haematol. 2020;45(1):35–39. doi:10.4103/ejh.ejh_30_19
   Web of Science ®Google Scholar
• Yu F, Shuang F, Jihong Z. Expression of WT1 gene and clinical significance in childhood acute B-cell lymphocytic leukemia of different immunophenotypes. Eur J Immunol. 2019;49:1537–1537.
   Web of Science ®Google Scholar
• Huang QS, Wang JZ, Qin YZ, et al. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Adv. 2019;3(21):3406–3418. doi:10.1182/bloodadvances.2019000564
   PubMed Web of Science ®Google Scholar
• Du X, Geng S, Weng J, et al. WT1 mRNA expression is a good laboratory indicator for diagnosis of disease progression in MDS patients with stable disease. Leukemia Res. 2017;55:S133. doi:10.1016/S0145-2126(17)30342-9
   Web of Science ®Google Scholar
• Zhang HY, Geng SX, Li MM, et al. Changes of WT1 mRNA expression level in patients with myelodysplastic syndromes after hypomethylating agents and its prognostic significance. Zhonghua Xue Ye Xue Za Zhi. 2019;40(5):417–421.
   PubMedGoogle Scholar
• Jiang Y, Liu L, Wang J, et al. The Wilms’ tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis. Oncotarget. 2018;9(22):16205–16212. doi:10.18632/oncotarget.23671
   PubMedGoogle Scholar
• Nagasaki J, Aoyama Y, Hino M, et al. Wilms tumor 1 (WT1) mRNA expression level at diagnosis Is a significant prognostic marker in elderly patients with myelodysplastic syndrome. Acta Haematol. 2017;137(1):32–39. doi:10.1159/000452732
   PubMed Web of Science ®Google Scholar
• Maeda T, Matsuda A, Asou C, et al. Prognostic impact of peripheral blood Wilms’ tumour 1 mRNA expression levels in response to azacytidine in MDS: a single-centre analysis. Leuk Res Rep. 2021;15:100231.
   PubMedGoogle Scholar
• Rautenberg C, Germing U, Pechtel S, et al. Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. Blood Cancer J. 2019;9(11):86. doi:10.1038/s41408-019-0248-y
   PubMedGoogle Scholar
• Anuchapreeda S, Rungrojsakul M, Tima S, et al. Co-activation of WT1 and AP-1 proteins on WT1 gene promoter to induce WT1 gene expression in K562 cells. Cell Signal. 2019;53:339–347. doi:10.1016/j.cellsig.2018.11.001
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Li X, et al. Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells. Oncol Lett. 2017;14(3):3862–3868. doi:10.3892/ol.2017.6628
   PubMed Web of Science ®Google Scholar
• Svensson E, Vidovic K, Lassen C, et al. Deregulation of the Wilms’ tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Leukemia. 2007;21(12):2485–2494. doi:10.1038/sj.leu.2404924
   PubMed Web of Science ®Google Scholar
• Ullmark T, Montano G, Järvstråt L, et al. Anti-apoptotic quinolinate phosphoribosyltransferase (QPRT) is a target gene of Wilms’ tumor gene 1 (WT1) protein in leukemic cells. Biochem Biophys Res Commun. 2017;482(4):802–807. doi:10.1016/j.bbrc.2016.11.114
   PubMed Web of Science ®Google Scholar
• El-Menoufy MAM, Ahmed MAR. Wilms’ tumor gene 1 expression can predict sudden disease progression to blast crisis in patients with chronic myeloid leukemia receiving imatinib therapy. Egypt J Haematol. 2018;43(1):38–43. doi:10.4103/ejh.ejh_5_18
   Web of Science ®Google Scholar
• Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204–212. doi:10.1038/ng.3742
   PubMed Web of Science ®Google Scholar
• Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373–379. doi:10.1038/s41586-018-0436-0
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195–5201. doi:10.1200/JCO.2009.22.4865
   PubMed Web of Science ®Google Scholar
• Dijk J, Knops G, Locht L, et al. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol. 2002;118(4):1027–1033. doi:10.1046/j.1365-2141.2002.03728.x
   PubMed Web of Science ®Google Scholar
• Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93(6):921–924. doi:10.3324/haematol.12165
   PubMed Web of Science ®Google Scholar
• Cho BS, Min GJ, Park SS, et al. WT1 measurable residual disease assay in patients With acute myeloid leukemia Who underwent allogeneic hematopoietic stem cell transplantation: optimal time points, thresholds, and candidates. Biol Blood Marrow Transp. 2019;25(10):1925–1932. doi:10.1016/j.bbmt.2019.05.033
   PubMed Web of Science ®Google Scholar
• Nomdedéu JF, Esquirol A, Carricondo M, et al. Bone marrow WT1 levels in allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplasia: clinically relevant time points and 100 copies threshold value. Biol Blood Marrow Transplant. 2018;24(1):55–63. doi:10.1016/j.bbmt.2017.09.001
   PubMed Web of Science ®Google Scholar
• Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood. 2002;99(9):3272–3279. doi:10.1182/blood.V99.9.3272
   PubMed Web of Science ®Google Scholar
• Plantinga M, Presti L, de Haar V, et al. Clinical grade production of wilms’ tumor-1 loaded cord blood-derived dendritic cells to prevent relapse in pediatric AML after cord blood transplantation. Front Immunol. 2020;11:559152. doi:10.3389/fimmu.2020.559152
   PubMed Web of Science ®Google Scholar
• Almshayakhchi R, Nagarajan D, Vadakekolathu J, et al. A novel HAGE/WT1-ImmunoBody(R) vaccine combination enhances anti-tumour responses when compared to either vaccine alone. Front Oncol. 2021;11:636977. doi:10.3389/fonc.2021.636977
   PubMed Web of Science ®Google Scholar
• Gao LQ, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34 + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95(7):2198–2203. doi:10.1182/blood.V95.7.2198
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5(174):174ra127. doi:10.1126/scitranslmed.3004916
   Web of Science ®Google Scholar
• Spira A, Hansen AR, Harb WA, et al. Multicenter, open-label, phase I study of DSP-7888 dosing emulsion in patients with advanced malignancies. Target Oncol. 2021;16(4):461–469. doi:10.1007/s11523-021-00813-6
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Bernal Y, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224–234. doi:10.1182/bloodadvances.2017014175
   PubMed Web of Science ®Google Scholar
• Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713–1721. doi:10.1182/blood-2017-04-780155
   PubMed Web of Science ®Google Scholar
• Minagawa H, Hashii Y, Nakajima H, et al. Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. BMC Cancer. 2023;23(1):167. doi:10.1186/s12885-023-10547-5
   PubMed Web of Science ®Google Scholar
• Kiguchi T, Yamaguchi M, Takezako N, et al. Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. Cancer Immun Immunr. 2022;71(6):1419–1430. doi:10.1007/s00262-021-03074-4
   PubMed Web of Science ®Google Scholar
• Naoe T, Saito A, Hosono N, et al. Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide. Cancer Immunol Immunother. 2023;72(8):2865–2871. doi:10.1007/s00262-023-03432-4
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Kitagawa K. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Hum Vaccin Immunother. 2018;14(1):159–162. doi:10.1080/21645515.2017.1382787
   PubMed Web of Science ®Google Scholar
• Tawara I, Kageyama S, Miyahara Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985–1994. doi:10.1182/blood-2017-06-791202
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019;25(7):1064–1072. doi:10.1038/s41591-019-0472-9
   PubMed Web of Science ®Google Scholar
• van Amerongen RA, Hagedoorn RS, Remst DFG, et al. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma. J Immunother Cancer. 2022;10(6):e004409. doi:10.1136/jitc-2021-004409
   PubMed Web of Science ®Google Scholar
• Walters JN, Ferraro B, Duperret EK, et al. A novel DNA vaccine platform enhances neo-antigen-like T cell responses against WT1 to break tolerance and induce anti-tumor immunity. Mol Ther. 2017;25(4):976–988. doi:10.1016/j.ymthe.2017.01.022
   PubMed Web of Science ®Google Scholar
• Chaise C, Buchan SL, Rice J, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008;112(7):2956–2964. doi:10.1182/blood-2008-02-137695
   PubMed Web of Science ®Google Scholar
• Kim HJ, Sohn HJ, Hong JA, et al. Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial. Bone Marrow Transplant. 2019;54(6):903–906. doi:10.1038/s41409-018-0383-2
   PubMed Web of Science ®Google Scholar
• Koehne G, Devlin S, Landau H, et al. WT1 heteroclitic epitope immunization following autologous stem cell transplantation induces WT1-specific immune responses and improves survival in patients with high-risk multiple myeloma. J Clin Oncol. 2017;35:8016. doi:10.1200/JCO.2017.35.15_suppl.8016
   Web of Science ®Google Scholar
• Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia. 1992;6(5):405–409.
   PubMed Web of Science ®Google Scholar
• Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90(2):194–204. doi:10.1111/j.1349-7006.1999.tb00733.x
   PubMedGoogle Scholar
• Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol. 2000;164(4):1873–1880. doi:10.4049/jimmunol.164.4.1873
   PubMed Web of Science ®Google Scholar
• Oka Y. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101(38):13885–13890. doi:10.1073/pnas.0405884101
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–5337. doi:10.1158/1078-0432.CCR-09-0737
   PubMed Web of Science ®Google Scholar
• Wang BH, Guan W, Lv N, et al. Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia. Hematology. 2021;26(1):371–379. doi:10.1080/16078454.2021.1921434
   PubMed Web of Science ®Google Scholar
• Wang XR, Chang Y, Yuan XY, et al. Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia. Ann Hematol. 2020;99(2):215–221. doi:10.1007/s00277-019-03808-6
   PubMed Web of Science ®Google Scholar
• Ueda Y, Ogura M, Miyakoshi S, et al. Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome. Cancer Sci. 2017;108(12):2445–2453. doi:10.1111/cas.13409
   PubMed Web of Science ®Google Scholar